Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab + PTCy + Tacrolimus for GVHD Prevention After Reduced Intensity Allogeneic HCT
NCT06815003Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2025
- Primary completion
- Oct 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in graft-versus-host disease (GVHD), sponsored by City of Hope. Started Apr 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06815003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815003.